Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)(☆)

BACKGROUND: We report results from the phase I dose-finding and phase II expansion part of a multicenter, open-label study of single-agent lenvatinib in pediatric and young adult patients with relapsed/refractory solid tumors, including osteosarcoma and radioiodine-refractory differentiated thyroid...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaspar, N., Campbell-Hewson, Q., Gallego Melcon, S., Locatelli, F., Venkatramani, R., Hecker-Nolting, S., Gambart, M., Bautista, F., Thebaud, E., Aerts, I., Morland, B., Rossig, C., Canete Nieto, A., Longhi, A., Lervat, C., Entz-Werle, N., Strauss, S.J., Marec-Berard, P., Okpara, C.E., He, C., Dutta, L., Casanova, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477142/
https://www.ncbi.nlm.nih.gov/pubmed/34562750
http://dx.doi.org/10.1016/j.esmoop.2021.100250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477142/
https://www.ncbi.nlm.nih.gov/pubmed/34562750
http://dx.doi.org/10.1016/j.esmoop.2021.100250

Ejemplares similares